• Cepton develops lidar sensors for ADAS and autonomous driving, and has been awarded the largest lidar production contract to date with products set to debut next year across General Motor’s Ultra Cruise ADAS platform
• Award covers 4 target vehicle models in 2023, 4+ models in 2024, and an anticipated 4+ models in 2025 with Cadillac being the first to introduce the Ultra Cruise technology
• Cepton’s proprietary MMT(R) technology provides a highly competitive price for performance and reliability
• Founder-led, visionary management team with substantial “skin in the game”

Since becoming public in early 2022, Cepton (NASDAQ: CPTN) has not deviated from its plan to be a leader in lidar. The Silicon Valley-based company made D-sample shipments in Q1 in support of GM’s Ultra Cruise program, which is the final stage before scale production, and is on-track to potentially be the world’s first lidar company to have its products found in consumer vehicles. Lidar, an acronym for light detection and ranging, is a remote sensing technology that bounces light off surrounding objects to accurately create a map of the environment. Lidar has been around for decades and has emerged as an integral component in advanced driver assistance systems (“ADAS”) and autonomous vehicles. In addition, lidar can be used in various non-automotive applications, enabling smart cities, automated tolling, last-mile delivery, autonomous trucking, robotics, etc. High cost has been one major problem with lidar systems for automakers, reserving it to only high-end models. Cepton has helped address this issue with its MMT(R) (micro-motion technology) lidar system, which was developed with mass market consumer vehicles in mind and has attracted the attention of top automotive OEMs (original equipment manufacturers) and Koito Manufacturing, a leading tier-1 automotive lighting supplier that has invested $100 million in Cepton. Cepton along with its tier-1 partner Koito Manufacturing is the recipient of the largest known ADAS lidar series production award to date with its lidar systems integrated into GM’s Ultra Cruise program. This program is expected to be released in 2023 on select GM vehicles with Cadillac being the first to introduce the technology. The Ultra Cruise advanced driver assist system is designed to enable door-to-door hands-free driving in 95 percent of all driving scenarios in North America. GM has agreed to use Cepton lidar products for its first 9 models that will offer Ultra Cruise in 2023 and 2024 and the companies are collaborating on potential additional models that will be introduced in 2025 and beyond. Cepton is currently engaged with all top 10 automotive OEMs worldwide. Cepton is advancing multiple projects worldwide in smart infrastructure. For example, Cepton partnered with The Indoor Lab to provide real-time crowd analytics at Orlando International Airport, which helped create one of the world’s safest terminals during the COVID-19 pandemic, covering roughly 50K square feet of terminal area. Cepton has recently worked with Fibre Based Integrations, an established fiber optics system house in South Africa to develop a lidar-based vehicle detection system in Cape Town to monitor lane usage. Cepton continues to invest in developing its portfolio of next generation products and technologies including its near range lidar, Nova, which were shipped to multiple global top-10 automotive OEMs (B-samples) for evaluation this quarter. The company also recently completed the architecture design for its second ASIC with tape out expected by the end of the year. This ASIC is a scalable companion chip to Cepton’s first ASIC with an emphasis on electronics component integration that reduces cost and dependency on the electronics supply chain. Cepton announced this month the opening of its new corporate office in Metro Detroit (Troy, MI) to serve as its automotive hub as the company continues to expand its active engagements and initiatives with OEMs. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

• Golden Matrix Group recently reported its 15th consecutive quarter of profitability
• GMGI’s second quarter revenues rose 221% YoY with net income expanding by upwards of 359% YoY
• GMGI attributed the rise in revenues to the added contribution from UK-based competition company, RKingsCompetitions Ltd, which Golden Matrix acquired in November 2021
• Management expressed their continued optimism on GMGI’s future prospects, with the company’s B2B and B2C verticals both showing robust growth

Fifteen consecutive quarters of profitability is a remarkable feat; even Amazon, the world’s largest e-commerce operator, reported a net loss over the past three months. Moreover, Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, achieved the feat in impressive fashion. The company recently reported financial results for its second fiscal quarter, with quarterly revenues rising by 221% year-over-year to $8,482,743. Meanwhile, Q2 net income rose to $586,984, a significantly increase relative to the $127,986 recorded in the equivalent period a year ago (https://ibn.fm/fBB9z). Golden Matrix Group attributed part of the significant increase in year-over-year revenues to the 28% increase in GMGI’s B2B segment’s top-line, in addition to strong revenue contributions from RKings. Golden Matrix Group acquired an 80 percent controlling stake in UK-based RKingsCompetitions Ltd in November 2021, with the company contributing 60 percent of GMGI’s total revenues in the quarter. Notably, GMGI also recorded a significant boost to their net income margin, with the latter figure expanding from 4.85 percent in Q2 last fiscal year to 6.92 percent in the most recent quarter. Perhaps more impressively, the company’s net margin widened despite a significant rise in GMGI’s cost base, with general and administrative expenses rising 321 percent year-over-year to $1,380,706 in the most recent quarter. The increase in costs was primarily due to G&A expenses arising from the RKings acquisition, which included payroll costs as well as bank charges for transaction fees. “We are pleased with the financial results of our second quarter as a company with both B2B and B2C verticals,” said Golden Matrix CEO Brian Goodman. “During the quarter we implemented upgraded technology and stronger accounting controls to improve cash flow and profitability at RKings. With the Tournament Platform’s added features and functionality, we expect steady increases in both the monthly number of skill tournaments and participants; and, because this robust platform gives RKings’ tournament players immediate access to a growing number of exciting prize competitions, we expect this third quarter and future quarters to generate increasing revenues and profits. GMGI has recently targeted its efforts on growing out both, their B2B and B2C verticals in recent months. On the B2B side, the company recently announced the launch of their revamped GM-X turnkey solution, a complete software package designed to support online gaming businesses. Benefitting from their partnership with upwards of 25 providers, GMGI have established a robust portfolio of over 10,000 games ranging from online slots, casino table games, live operator games, and more, which are then licensed to gaming platform operators seeking to operate a proven set-up. Golden Matrix Group have also simultaneously sought to grow out their B2C segment, most recently through the acquisition of RKingsCompetitions Ltd. In addition to contributing approximately $5.1 million of the group’s total revenues for the quarter, RKings’s unique competitions have also resulted in GMGI acquiring over forty five thousand new players a quarter at relatively low cost – a crucial factor towards growing out their addressable consumer universe going forward. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

• Drug delivery technology innovator Lexaria Bioscience has developed a patented technology showing superiority in animal and human testing as a means of improving existing drug brands’ performance and establishing new solutions for unmet medical needs
• The company recently announced agreements with beverage developer BevNology to expand production capabilities for Lexaria’s own growing list of B2B clientele and empowering BevNology to offer DehydraTECH products with active ingredients derived from hemp including CBD under BevNology and partnered brands
• The technology is called DehydraTECH — improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery
• Lexaria also recently announced an agreement with Ireland’s Anodgen Bioceuticals that allows Anodgen to manufacture and distribute DehydraTECH processed cannabinoid API powders within Europe including the UK, Australia and New Zealand

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has built the reputation of its patented DehydraTECH drug delivery technology through a growing data set of potential medicinal applications and through an expanding list of licensing agreements with third-party companies interested in its potential for cannabidiol (“CBD”)-based products. Lexaria’s patented DehydraTECH technology transforms a wide variety of orally and topically administered products into enhanced solutions that make the APIs more rapidly available and effective at lower doses while adding zero chemical byproducts. Among the licensing partnerships announced by the company are recent agreements with beverage developer BevNology and Ireland API manufacturer and distributor Anodgen Bioceuticals. The BevNology collaboration was announced June 21 and not only includes a commercial license agreement for products with active ingredients derived from hemp under BevNology’s brand, but also a manufacturing operating agreement utilizing BevNology’s new, custom-built state-of-the-art processing facility outside Atlanta. “These agreements build on a long standing and very successful product development consulting relationship between Lexaria and the expert scientists and personnel at BevNology,” Lexaria CEO Chris Bunka stated in announcing the BevNology development (https://ibn.fm/wb0e3). “BevNology’s formulation and production capabilities are class leading and we are confident that our new relationship with our trusted partner will propel new and exciting growth opportunities for both companies.” The manufacturing agreement will help Lexaria broaden its production capabilities for its own growing list of B2B clientele interested in purchasing DehydraTECH-powered active ingredients for consumer packaged-goods brands.  Lexaria has already installed all required commercial DehydraTECH manufacturing equipment at the facility. The licensing agreement addresses powdered DehydraTECH formulations and liquid formulations that tend toward BevNology’s particular expertise. Both elements of the agreement are non-exclusive, except that the liquid formulations have limited exclusivity in the United States and complete exclusion in Japan, the Republic of Korea, and the People’s Republic of China. The Anodgen licensing agreement was announced earlier in the month and includes a five-year non-exclusive DehydraTECH license for powdered CBD-based products in Europe including the United Kingdom, Australia, and New Zealand. Under the license, Anodgen can use DehydraTECH not only for making and selling medical application CBD products but also pharmaceutical applications for psychoactive cannabinoids (https://ibn.fm/aXPCD). Anodgen is building a new facility in Ireland and expects to be fully operational later this year, creating the potential for long-term use of DehydraTECH for the pharmaceutical market. Independent third-party testing has evidenced DehydraTECH’s ability to enhance the performance of a variety of pharmaceutical and wellness industry products and has led to a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) to file DehydraTECH-CBD as a prospective registered treatment for hypertension this year (https://ibn.fm/w5xaX). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Odyssey Health is focused on developing life-saving medical products and pharmaceutical assets that offer a technological and clinical advantage
• The company is developing the CardioMap Heart Monitoring and Screening Device and the Save-a-Life choking rescue device
• Its drug-device combination is intended to get PRV-002, Odyssey’s novel treatment for concussion, to the brain rapidly after concussion
• In an interview with RedChip Companies CEO Dave Gentry, Odyssey CEO Michael Redmond outlined the timelines under which the company is operating as it eyes the commercialization of its novel drug candidate

Medical company Odyssey Health (OTC: ODYY) is working to provide life-saving medical solutions that offer clinical advantages to unmet medical needs. The company boasts a repertoire of several products that include the CardioMap Heart Monitoring and Screening Device and the Save-a-Life choking rescue device, both of which are in development and are, therefore, not yet commercially available, as well as a novel breath-propelled nasal delivery device designed to deliver the company’s novel treatment for concussion, PRV-002. Nasal Delivery Device The nasal delivery device, which was the subject of a patent application filed last fall (https://ibn.fm/9c2KZ), is part of a drug-device combination that is being used in Odyssey’s ongoing Phase I clinical trial investigating how well PRV-002 is tolerated by healthy human subjects. “It’s a small device that essentially delivers a powdered drug through the upper chambers of the nasal cavity. The drug crosses the blood-brain barrier within 5 minutes and spreads out throughout the brain within 30 minutes, reversing the effects of a concussion,” explained Odyssey CEO Michael Redmond in a recent interview with RedChip Companies CEO Dave Gentry (https://ibn.fm/Pz8SE). The device provides Odyssey with the opportunity to get PRV-002 into the brain rapidly after a concussion, a factor that, coupled with the drug’s safety profile and lack of adverse side effects as indicated by extensive animal trials and initial results from a section of the participants in the Phase I clinical trial, will be instrumental to the company’s success in its clinical trials. PRV-002 Novel Drug Candidate Developed by two neuroscientists, one of whom has a background as a toxicologist, PRV-002 is a compound that Redmond described as a drug cocktail containing three new, proprietary elements that have three mechanisms of action. “Between the two of them, having both toxicology and neurological backgrounds, they created an extremely safe drug compound. We did animal studies that show even at 200 times what we believe to be the dosing, there’s still no toxicity. So, it’s an extremely safe drug, and the efficacy in the animal models is very strong. We have confidence that this will translate into humans,” Redmond continued. The PRV-002 drug is designed to be administered as close to a concussion event as possible, with quicker administration leading to better results. Odyssey has established that there is a window of at least six hours within which the drug shows greater efficacy, if administered. To boost the chances of greater efficacy from quick administration, the PRV-002 drug candidate is available as a dry powder with a long shelf life and does not require special handling or refrigeration. For this reason, it can sit on the sidelines of any football game or sporting event. In addition, soldiers, who are at great risk of suffering blunt trauma from explosives’ shockwaves, bullet penetration, and violent impact, can store it in their backpacks, while emergency response teams can keep it in their ambulances or emergency rooms (“ERs”). When asked how quickly the company expects to begin Phase II clinical trials given the ongoing Phase I clinical trial, Redmond noted, “When we have the Phase I data, we can actually start a Phase II trial in Australia immediately. We have a site set to start a Phase II trial in Australia, likely in the October timeframe. We want to do some of the Phase II or most of it in the U.S., and that requires FDA approval. We have reached out to the FDA to set up that meeting, and hopefully, we’ll have a meeting with the FDA where we can provide our Phase I data in the summer timeframe.” The company is in discussions with the military in the U.S. to undertake the Phase II study at some of the military sites that experience a large number of concussions and has, in fact, formed a Military Advisory Board to help it achieve this goal (https://ibn.fm/j4LAw). Odyssey expects to “be in the U.S. Phase II [clinical trial stage] this year, probably in the fourth quarter,” subject to FDA approval. Strategic Approach Odyssey has strategically planned its Phase II trial to ensure it collects data as soon as the study commences. According to Redmond, the ability to gather data is a function of the number of concussed patients, meaning the company has to set trials at sites that report a high number of concussions. For example, the military has at least two sites that experience over 100 concussions a month. And by setting up the trials at these sites, the company expects to start collecting data immediately upon the start of the trial. Redmond also highlighted the subsequent phases of its drug development journey, noting that the drug could be available for commercialization to Special Populations – a group of people, in this case, the military, that experiences concurrent disease states (https://ibn.fm/O9jh7) – immediately after a successful Phase II trial. That’s because there is currently no FDA-approved treatment for concussion. To facilitate this milestone, Odyssey would be open to partnerships for commercialization, marketing, and distribution. For more information, visit the company’s website at https://odysseygi.com/. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• New meal plan offering includes three meals a day (breakfast, lunch and dinner) up to five days per week
• Model Meals brand is optimal for providing seamless customer experience, substantially increased customer lifetime value
• Move provides opportunity to explore subscription model with other HBIS components, says CEO

Home Bistro (OTC: HBIS), a leading online meal-delivery platform that offers exclusive celebrity chef-inspired, gourmet and lifestyle ready-made meals, is strengthening its commitment to offer exclusive celebrity-chef-inspired, ready-made meals by launching its first subscription-based offering for its Model Meals brand (https://ibn.fm/9wDv9). The new plan offering includes three meals a day (breakfast, lunch and dinner) up to five days per week. “We are excited to finally execute on a long-term strategic objective by establishing a subscription-based meal platform,” said Zalmi Duchman, Home Bistro CEO. “We believe the Model Meals lifestyle brand is optimal for establishing a sticky, recurring revenue model, which provides for a seamless customer experience and a substantially increased customer lifetime value. This also gives us an opportunity to explore the subscription model with other components of our business.” Initially HBIS will offer the subscription-based plans in its southern California market, with plans to expand moving forward. Home Bistro acquired Model Meals in July 2021 in a strategic move to extend its food-production and fulfillment capabilities to the western region of the United States (https://ibn.fm/0JwbH). “This acquisition provides Home Bistro with major benefits on multiple levels,” said Home Bistro CEO Zalmi Duchman. “First, given our now bicoastal operations, we have the ability to ship overnight to most customers within the 48 contiguous states. Next, we acquired a lifestyle brand that has the potential for recurring revenue, subscription-based enrollment and potential for growth to the other 47 states from the current three. Lastly, we add tremendous talent to the Home Bistro management team with Camille, Danika and the senior staff at Model Meals.” Home Bistro’s Model Meals lifestyle brand is a Whole30- and Paleo-approved, ready-to-eat, meal-prep service (https://ibn.fm/RVPRO). The platform offers a weekly menu that rotates. Meal plans are prepared by professional chefs, using only the highest-quality ingredients available, which are sourced responsibly and locally, and delivered in sustainable, ecofriendly packaging. The strategic movement by HBIS comes as a Mordor Intelligence study reports that the “the global ketogenic diet food market is projected to register a CAGR of 5.52% during the forecast period, 2022—2027” (https://ibn.fm/cwJMh). The report notes that the global pandemic and the fact that “online health training websites and various social media platforms have been promoting to intake of healthy diets . . . has increased the consumption of keto-based food and beverage at a faster growth.” For more information, visit the company’s website at www.HomeBistro.com. NOTE TO INVESTORS: The latest news and updates relating to HBIS are available in the company’s newsroom at https://ibn.fm/HBIS

• Study indicates that ketamine-induced changes in functional connectivity last for several days after administration of the substance
• Kernel Flow gathers real-time functional brain activity during clinical and research studies evaluating psychedelic-based therapeutics
• Technology is “precisely what we need to accelerate the development of psychedelics into therapeutics,” says Cybin CEO

New data confirms Cybin’s (NEO: CYBN) (NYSE American: CYBN) focus on and commitment to progressing psychedelics to therapeutics. The company’s feasibility study using Kernel Flow confirms the device’s ability to successfully measure the neuro-effect of ketamine (https://ibn.fm/blLwT), based on study results presented at the PSYCH Symposium in London. Cybin has announced that preliminary data from the study indicate that ketamine-induced changes in functional connectivity last for several days after administration of the substance. Kernel Flow is the first easy-to-use, wearable device that collects and measures real-time brain activity before, during and after a psychedelic experience. Using the device, the study successfully measured the neuro-effect of ketamine over 11 days, confirming changes in functional connectivity that are consistent with current scientific research. “Previously, studies had to rely on subjective patient reporting,” said Cybin CEO Doug Drysdale. “By utilizing Flow, we will now be able to quantifiably gather real-time functional brain activity during our clinical and research studies evaluating psychedelic-based therapeutics. “Measuring where and how psychedelics work in the brain unlocks new frontiers of discovery in this space,” Drysdale continued. “Most importantly, Kernel Flow will enable us to measure the duration of effect during a psychedelic experience, which will be pivotal in developing the most accurate and effective treatment regimens for patients. This technology is precisely what we need to accelerate the development of psychedelics into therapeutics.” Cybin is partnering with Kernel, a leader in noninvasive neuroimaging, for the study. During the study, participants receive either a low dose of ketamine or a placebo while wearing the Flow headset, which measures cortical hemodynamics experienced during an altered state of consciousness. Data was collected to create a baseline at days 1 through 5, with a dosing administered at day 6, then follow-up data was collected on days 7 through 11, confirming that ketamine-induced changes in functional connectivity lasted for several days after participants received the substance. “Kernel Flow is a groundbreaking neuroimaging technology that enables rigorous characterization and quantification of physiological processes in the human brain,” said Bryan Johnson, Founder and Chief Executive Officer of Kernel. “We’re excited to report the pilot results of a longitudinally rich dataset of brain activity before, during a ketamine-induced altered-state experience, and after. The quality of the data recorded with Flow may lead to a better understanding of the neuro effects from psychedelics on the brain and help advance these powerful new therapies for patients.” The feasibility study involves participants wearing Kernel Flow, which features hi-tech sensors to record brain activity, while in an altered state of consciousness following the administration of ketamine. The system records brain activity throughout the four-week study, which is combined with information gathered from questionnaires and validated assessments. Information from the study may be used by Cybin as it develops its two active drug programs, CYB003 and CYB004, which target anxiety and depression (https://ibn.fm/nULws), (https://ibn.fm/gQjHz). CYB003 is a deuterated psilocybin analog derived from psilocybin that is designed to achieve less variability in plasma levels, a faster onset of action and shorter duration of effect, as well as potentially better tolerability, for an overall better outcome for patients. CYB004 is a deuterated dimethyltryptamine (“DMT”) that, in its natural form, is rapidly metabolized in the body, unstable and not orally bioavailable. However, preclinical studies show the potential for overcoming these limitations such that deuterated DMT could provide increased oral and pulmonary bioavailability and faster onset, with lower doses, less patient variability, and better dose titration, resulting in fewer side effects and longer-acting desensitization of the serotonergic receptors. CYB004 is also being evaluated for its potential to effectively treat anxiety disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

Sustain Southern California (“Sustain SoCal”) accelerates cleantech economic growth and sustainability initiatives through innovation, collaboration, and education. Sustain SoCal is hosting Driving Mobility – the 9th Annual Transportation Conference. This year’s event will feature succinct presentations by leading c-suite executives, senior management, and industry experts from public sector organizations. Invited speakers will share their perspectives on a multitude of issues, including electrification, V2X, hydrogen/fuel cell, OEM and investor trends, connected vehicles, mobility as a service, incentives, policy, legislation, and sustainability. Mobility and transportation experts, representatives of local and state authorities, potential investors from private equity and venture capital, experts from the battery storage subsector, university faculty, and senior executives from marquee companies such as Virgin Galactic and Volvo N.A., that specialize in mobility and transportation will be in attendance. Key aspects of this event:

• Driving Mobility 9 is a one-day in-person event. The conference will be from 1:00-5:00 pm and the EXPO and reception will be held from 5:00-7:30 pm
• The event will take place at UCI Beall Applied Innovation
• The event is free of cost for Sustain SoCal Members.
• Presentations will be brief, packed with information, insights, and to the point.
• The event will also host an Innovators Showcase, where c-suite executives will present their latest research and development to attendees.
• An in-person EXPO and reception will be held to conclude the event.

Who’s Organizing This Event? Sustain SoCal is a non-profit organization based at UCI Beall Applied Innovation, that proactively addresses Southern California’s sustainability, environmental and infrastructure needs and objectives. The organization gathers stakeholders via industry-leading conferences, workshops, and networking events to positively impact the region’s economic progress and sustainable future. During its long history, Sustain SoCal has focused on key sectors such as Energy, Water, Agriculture, Transportation, Hospitals and Healthcare, and Waste Stream Management. The organization aims to foster cooperation and collaboration among the public, private and academic sectors in the area of sustainability and cleantech within and around the greater Southern California region while serving as an information hub, a platform for advocacy, and providing mentorship and advisory with a view to further sustainable linkages. Sustain SoCal invites established and emerging cleantech companies, start-up companies, corporate organizations of all sizes, municipal/regional/state/national agencies, non-profit organizations, and investors to register for the event. Why Should You Attend? The Driving Mobility 9 event presents a unique opportunity to build a deep understanding of the evolving trends in mobility and advanced transportation. The event will host several industry stalwarts and sector experts, who will provide an insightful commentary on the state of the sector and future opportunities. Attendees will be able to learn from and interact directly with thought leaders across various sub-sectors in the mobility and transportation landscape. Furthermore, the event will provide a forum for exchanging ideas and exploring business opportunities and enable networking with large corporations, cleantech companies, local government, investors, academia, and non-profits. In addition, it will provide a platform to share best practices, a deeply educational experience for the broader community to engage with clean technology, and potential financial opportunities for investment professionals. How To Register? For more information on the event, visit here. To register, please submit the registration form at the earliest. For SoCal members, the event is free. So why wait?

• Two years after a vaccine was made available for COVID-19, fewer than 70% of Americans have been vaccinated
• The AditxtScore(TM) can provide the necessary answers to individualized immune response questions and direct on the best course of treatment for the individual – not the herd
• No additional funding for COVID-19 relief has been approved by Congress, requiring the Biden Administration to reallocate funds to prepare for the fall months and uptick in virus counts
• The reallocation of funds for further vaccine development has reduced the amount spent on testing efforts causing concern for epidemiologists due to the lack of variant tracking

The COVID-19 pandemic, from the start, has been characterized by the high unpredictability of the virus. Despite the best efforts of the scientific community to use the historical data and patterns of previous viruses, it is becoming apparent that the original presumptions are no longer valid. The original hypothesis was that once enough people created an immunity to COVID-19, it would stop the virus dead in its tracks; unfortunately, what they are learning is that herd immunity is unlikely to happen. Herd immunity occurs when a virus can’t spread because it keeps encountering people who have become immune to the specific virus. The idea is that a small group of people lacking resistance to the virus can be protected by the immune herd because it is less likely to spread to them. Even though the mentality that herd immunity can be successful through immunizations, scientists no longer believe that this is an appropriate management strategy for COVID-19 long-term. Two years after a COVID-19 vaccine was made available, fewer than 70% of Americans are fully vaccinated (https://ibn.fm/lcOKY). The pockets of unvaccinated people who lack any type of immunity to this ever-changing virus only provide the potential for the virus to grow and mutate as it spreads. Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, has partnered with Premier Medical Laboratory Services to provide individuals with personalized information regarding their immune system via the AditxtScore(TM). The score can be used to provide those tested with important answers to questions like:

• Are antibodies present?
• How are these antibodies present – vaccine or natural immune system response?
• Will this immunity status provide protection from the virus in the future?
• What is the best approach to creating immunity for that individual?

“As new variants emerge, we want to equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status,” Kevin Murdock, CEO of Premier Medical Laboratory Services, stated (https://ibn.fm/pbmD3). “With AditxtScore(TM), individuals can make more informed decisions about whether vaccination, boosters, or other risk mitigation strategies are the right course of action for them.” With the potential for herd immunity off the table, and federal COVID funds dwindling, supply rationing has begun. Of the current budget, the Biden Administration has reallocated $5 billion to purchase updated versions of the vaccine for fall. Since Congress has approved no new funding, the Administration is forced to use the remaining budget to consider the longer-term solutions, like fall when virus uptick increases. At this time, epidemiologists are concerned about the blind spots created due to the shift in focus from testing to more vaccine development. Without the increased testing efforts, it becomes impossible to track and isolate variants. Without the funding, further development on the COVID-19 front will be less likely to be sustainable. About Aditxt Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies. For more information, visit the company’s websites at www.Aditxt.com and www.AditxtScore.com. NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

• Flora Growth Corp. announced that the Company Board has authorized the repurchase of up to $5 million of its outstanding common shares
• Luis Merchan, Flora’s Chairman and CEO, said that Flora is executing its growth plans while simultaneously improving gross profit margins and reducing corporate overhead expenses
• At the closing of 2021, the company announced a 2022 revenue guidance projection of $35-45 million

Flora Growth (NASDAQ: FLGC) is a global leader in the cultivation, marketing, and distribution of premium-quality cannabis products and brands at below-market prices. Flora Growth recently announced that the company’s Board of Directors (the “Board”) has authorized the repurchase of up to $5 million of its outstanding common shares subject to market conditions and the company’s liquidity warrant (https://ibn.fm/MN24h). Luis Merchan, Flora’s Chairman and CEO, stated that the potential to repurchase their shares at these levels represents a compelling opportunity to deploy available cash to drive shareholder value. The company’s board believes that the decline in the market price of shares is due to the generally weak financial market and cannabis sector. It is also attributed to the recent selling of several millions of shares by certain shareholders who acquired such shares at a very low-cost basis, prior the company’s had its IPO, and who had previously been subject to a one-year lockup period which expired in mid-May. Repurchases may be made from time to time through open market purchases, and, in no event shall the company repurchase more than five percent of the total number of issued and outstanding shares as of the repurchase date. Flora’s 249-acre cultivation facility Cosechemos, based in Colombia, is the core of the company’s business model. The ideal location, resources, and climatic conditions at the Cosechemos farm, enable Flora’s low production cost which is approximately $0.06/gram, compared to production costs that can be as high as $1/gram or more in parts of North America (https://ibn.fm/AmzIv). On Feb 22, 2022, Columbia’s President Duque approved a previously announced legislation expanding on Resolution 811.  The new Resolution 227 allows the industrial use of cannabis in sectors such as food, beverages and textile. This new regulation will further pave way for increased revenues for the company (https://ibn.fm/IKQjp). Recently, Flora also solidified its foothold in the U.S., by acquiring the luxury cannabis consumer brand Vessel Brand Inc. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• SGMD will produce an estimated 25,000 pounds of Fresh Frozen cannabis, which Cannabis Global will use in its product lines
• The market for Fresh Frozen cannabis is “snowballing,” says Cannabis Global CEO
• With the rapid Fresh Frozen harvesting process, airtight storage and near cryogenic storage temperatures, almost all of the natural cannabis plant essence is preserved

Sugarmade (OTC: SGMD), an emerging leader in the licensed cannabis sector, is seeing the fruit of its labors, so to speak. The company recently announced the first transaction under its previously announced contract with Cannabis Global (OTC: CBGL). The transaction calls for Sugarmade to produce an estimated 25,000 pounds of Fresh Frozen cannabis, which Cannabis Global will use in its product lines and will distribute to the California marketplace (https://ibn.fm/l3QJa). Sugarmade and Cannabis Global have signed a prebooked, fixed-price contract in the amount of $700,000; that payment includes cash payments from Cannabis Global to Sugarmade of $300,000 and notes for the balance of $400,000. Planting of the cultivators began in mid-May and will continue into early June. “The market for Fresh Frozen cannabis is snowballing,” said Cannabis Global CEO Arman Tabatabaei. “Thus we believe it is the place to be for the 2022 cultivation season. We plan to process a large portion of the 25,000 pounds of ultra-premium cannabis at our Lynwood, California, laboratory, creating premium solventless extracts for sale into the market and for use in our own manufactured products, thus creating vertical integration to reduce our costs of goods sold. “We also plan to store a significant portion of the biomass in the Los Angeles area to create an active wholesale market to the many new solventless extractors in the area via our wholly owned distribution company, Northern Lights Distribution,” Tabatabaei continued. “We have integrated this cultivation effort into our strategic plan for 2022 and 2023 as an important component to further boost our already fast-growing revenue base.” Fresh Frozen cannabis is flash frozen immediately after harvest instead of undergoing the traditional treatment of drying and curing. A growing number of cannabis consumers are choosing this type of cannabis as they seek naturally produced cannabis products full of natural plant terpenes and flavors. As demand grows, the number of products available that contain Fresh Frozen cannabis is also growing. “In many ways, the advent of Fresh Frozen-oriented cannabis cultivation has turned the cannabis cultivation model on its head,” a recent article observed. “Where cultivators traditionally harvested cannabis plants and then spent weeks or months drying, curing and processing plant materials, all the while battling heat, humidity, molds and other factors that could affect the product. “Fresh Frozen-oriented cultivation allows growers to ditch the traditional model by cutting down the plants at the peak of freshness, stripping the large leaves, branches and stems and then bagging the remaining materials bound for storage in industrial freezers at temperatures well below -5 F,” the article continued. “With the rapid harvesting process, airtight storage and near cryogenic storage temperatures, almost all of the natural cannabis plant essence is preserved.” Sugarmade is a product and branding marketing company investing in operations and technologies with disruptive potential. The company’s brand portfolio includes CarryOutsupplies.com, SugarRush, NUG Avenue and Lemon Glow. For more information, visit the company’s website at www.Sugarmade.com. NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SGMD